Results 1 to 10 of about 38,387 (188)

Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study [PDF]

Therapeutic Advances in Gastroenterology
Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes.
Stephanie Coward, Karen J. B. Martins, Scott Klarenbach, Lawrence P. Richer, Christopher Ma, Remo Panaccione, Cynthia H. Seow, Karen Kroeker, Frank Hoentjen, Laura E. Targownik, Gilaad G. Kaplan   +10 more
doaj   +2 more sources

Is It Really Feasible to Use Budesonide–Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Previous studies suggest that inhaled budesonide-formoterol used as needed could effectively reduce the severe exacerbation of mild persistent asthma.
Xiang Tong, Tao Liu, Zhenzhen Li, Sitong Liu, Hong Fan   +4 more
doaj   +1 more source

Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging

Pharmaceutics, 2021
Direct lung administration of budesonide in combination with surfactant reduces the incidence of bronchopulmonary dysplasia. Although the therapy is currently undergoing clinical development, the lung distribution of budesonide throughout the premature ...
Riccardo Zecchi, Pietro Franceschi, Laura Tigli, Barbara Pioselli, Valentina Mileo, Xabier Murgia, Fabrizio Salomone, Giuseppe Pieraccini, Haruo Usada, Augusto F. Schmidt, Noah H. Hillman, Matthew W. Kemp, Alan H. Jobe   +12 more
doaj   +1 more source

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

BMJ Open Respiratory Research, 2022
Background In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta2-agonist (SABA) reliever in adolescent and adult asthma ...
, James Fingleton, Mark Weatherall, Richard Beasley, Irene Braithwaite, Ian Pavord, Jenny Sparks, Lee Hatter, Helen K Reddel, Robert J Hancox, Mark Holliday, Andrew Corin, Daniela Hall, Claire Houghton, Saras Mane, John Martindale, Karen Oldfield, Donah Sabbagh, Alexandra Vohlidkova, Alberto Papi, Allie Eathorne, Pepa Bruce   +21 more
doaj   +1 more source

New Strategies for Improving Budesonide Skin Retention

Pharmaceutics, 2021
The aim of this work was to evaluate the ex vivo effect of the combination of two strategies, complexation with cyclodextrin, and poloxamer hydrogels, for improving water solubility in the dermal absorption of budesonide.
Cristina Padula, Ian Pompermayer Machado, Aryane Alves Vigato, Daniele Ribeiro de Araujo   +3 more
doaj   +1 more source

Budesonide

Reactions Weekly, 2006
europepmc   +2 more sources

Budesonide Analogues Preserve Stem Cell Pluripotency and Delay 3D Gastruloid Development

Pharmaceutics, 2023
Small molecules that can modulate or stabilize cell–cell interactions are valuable tools for investigating the impact of collective cell behavior on various biological processes such as development/morphogenesis, tissue regeneration and cancer ...
Filomena Amoroso, Eduardo Ibello, Federica Saracino, Federica Cermola, Giovanna Ponticelli, Enrica Scalera, Francesca Ricci, Gino Villetti, Gilda Cobellis, Gabriella Minchiotti, Eduardo Jorge Patriarca, Dario De Cesare, Cristina D’Aniello   +12 more
doaj   +1 more source

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis

Therapeutic Advances in Gastroenterology, 2023
Background: Low bioavailability steroids, including beclomethasone dipropionate (BDP) and budesonide MMX, have been developed to ensure colonic targeting and low systemic activity than systematic corticosteroids in treating patients with ulcerative ...
Brigida Barberio, Ilaria Marsilio, Andrea Buda, Luisa Bertin, Gianluca Semprucci, Annalisa Zanini, Martina Crepaldi, Fabiana Zingone, Edoardo Savarino   +8 more
doaj   +1 more source

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. [PDF]

, 2015
BackgroundBudesonide foam, a rectally administered, second-generation corticosteroid with extensive hepatic first-pass metabolism, is efficacious for the treatment of mild-to-moderate ulcerative proctitis and ulcerative proctosigmoiditis.AimThe aim of ...
Barrett, Andrew C, Bortey, Enoch, Bosworth, Brian, Forbes, William P, Golden, Pamela L, Gordon, Glenn L, Rolleri, Robert L, Rubin, David T, Sale, Mark E, Sandborn, William J, Zakko, Salam   +10 more
core   +3 more sources

Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study

BMC Gastroenterology, 2022
Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation.
Ryosuke Miyazaki, Toshiyuki Sakurai, Mariko Shimada, Yuko Iwashita, Naoki Shibuya, Yoshihiro Akita, Haruna Miyashita, Yuki Maruyama, Masayuki Saruta   +8 more
doaj   +1 more source